SEC Form 4 · accession 0001209191-19-012010
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Interim CFO
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 4:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 19, 2019 | S | 1,668 | $186.72 | D | 18,903 | D | |
| Common StockF3,F4 | Feb 19, 2019 | S | 984 | $187.10 | D | 17,919 | D | |
| Common Stock | Feb 19, 2019 | S | 160 | $188.70 | D | 17,759 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $186.72 (range $185.93 to $186.93).
- F3Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $187.10 (range $186.95 to $187.42).